Bartosz K.
- Country
- Poland
- Department
- Klinika Kardiologii
Research Overview
- A Phase 3, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Levosimendan in Patients with Pulmonary Hypertension and HFpEF
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
Data & Insights
Has run more than one trial at 956 of 1639 partner sites.
Specializations
Heart Failure Research
The investigator specializes in various forms of heart failure conditions, with particular emphasis on both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). Their research encompasses innovative therapeutic approaches for chronic heart failure management.
- Chronic Heart Failure Treatment
- Advanced Heart Failure Therapies
- Cardiogenic Shock Management
Cardiac Conditions
The investigator focuses on treating complex cardiac conditions, including acute coronary syndrome and myocardial infarction. Their expertise extends to various forms of cardiomyopathy, particularly hypertrophic variants.
- Acute Coronary Syndromes
- ST-Elevation Myocardial Infarction
- Hypertrophic Cardiomyopathy
Cardiovascular Prevention
The investigator studies preventive approaches in cardiovascular medicine, focusing on atherosclerotic cardiovascular disease and heart failure prevention. Their work includes research on antiplatelet strategies and lipid-modifying therapies.
- Preventive Cardiology
- Atherosclerosis Management
- Cardiovascular Risk Reduction
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.